Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment—We Need to Know the When, What, and Who

Kebebew, Electron

doi:10.1001/jamaoncol.2021.6247

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of ultrasound technology, ultrasound-guided thermal ablation of PTMC can also achieve the same therapeutic effect as surgery. Currently, although THCA patients have high overall survival rate, worryingly, nearly 30% of whom have a 10-year recurrence rate, while the survival rate in these high-risk patients can be about 50% ( 9 ). It calls for innovative approaches to find critical biomarkers with sufficient sensitivity in the research on THCA.…”

Section: Introductionmentioning

confidence: 99%

Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma

Cai¹,

Niu²,

Gao³

et al. 2023

ijph

View full text Add to dashboard Cite

Background: Cuproptosis-related long non-coding RNA (lncRNA) disease is associated with the development and progression of tumors. We aimed to investigate the prediction of cuproptosis-related lncRNA on the prognosis and immunotherapy of patients with thyroid carcinoma (THCA). Methods: The thyroid cancer-associated expression data and lnc RNAs data were downloaded from The Cancer Genome Atlas (TCGA) and Ensembl database. The prognostic model of cuproptosis-related lncRNAs was successfully constructed through Lasso regression analysis and Cox regression analysis. Then, the prognostic value of prognostic model of cuproptosis-related lncRNAs was tested through the survival analysis, ROC curves and nomographic charts. Finally, the prognostic model of cuproptosis-related lncRNAs associated with immunity and mutational load of tumors was analyzed, and potential targeted drugs for THCA were predicted. Results: A cuproptosis-related lncRNA model of THCA (AC026100.1, AF235103.3, LNCSRLR) was successfully constructed, which has an independent prognostic value. Moreover, the cuproptosis-related lncRNA model was associated with immune signatures and mutational load in most tumors, showing its high correlation with the sensitivity of targeted drugs such as 5-Fluorouracil, Bleomycin, Rapamycin and Sunitinib. Conclusion: The cuproptosis-related lncRNA model of THCA has promising applications in the treatment and prognosis of THCA.

show abstract

Section: Introductionmentioning

confidence: 99%

Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma

Cai¹,

Niu²,

Gao³

et al. 2023

ijph

View full text Add to dashboard Cite

show abstract

Current advance of nanotechnology in diagnosis and treatment for malignant tumors

Wang,

Hu,

Teng

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary field that is garnering a lot of interest and investigation. Nanomedicine shows great potential for cancer diagnosis and treatment. Specifically engineered nanoparticles can be employed as contrast agents in cancer diagnostics to enable high sensitivity and high-resolution tumor detection by imaging examinations. Novel approaches for tumor labeling and detection are also made possible by the use of nanoprobes and nanobiosensors. The achievement of targeted medication delivery in cancer therapy can be accomplished through the rational design and manufacture of nanodrug carriers. Nanoparticles have the capability to effectively transport medications or gene fragments to tumor tissues via passive or active targeting processes, thus enhancing treatment outcomes while minimizing harm to healthy tissues. Simultaneously, nanoparticles can be employed in the context of radiation sensitization and photothermal therapy to enhance the therapeutic efficacy of malignant tumors. This review presents a literature overview and summary of how nanotechnology is used in the diagnosis and treatment of malignant tumors. According to oncological diseases originating from different systems of the body and combining the pathophysiological features of cancers at different sites, we review the most recent developments in nanotechnology applications. Finally, we briefly discuss the prospects and challenges of nanotechnology in cancer.

show abstract

Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment—We Need to Know the When, What, and Who

Abstract: Life expectancy is reduced in differentiated thyroid cancer patients Ն 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients.

Cited by 2 publications

References 7 publications

Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma

Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma

Current advance of nanotechnology in diagnosis and treatment for malignant tumors

Contact Info

Product

Resources

About